Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (2024)

About GNPX Financial Performance Analyst Forecast News Genprex to Present at the 2024 BIO International Convention Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner Genprex to Present and Participate at Upcoming May Investor and Industry Conferences Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators Genprex to Present at Upcoming BIO CEO & Investor Conference Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 Genprex Provides Business Update and Outlook for 2024 Genprex to Present at BIO-Europe 2023 Conference Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers" Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC Genprex to Present at Upcoming September Investor Conference Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules References